Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
暂无分享，去创建一个
E. Hitre | Chia‐Chi Lin | M. Brose | B. Keam | S. Sherman | D. Bowles | J. Capdevila | L. Faoro | J. Krajewska | F. Vaisman | J. Oliver | J. Hernando | B. Robinson | A. Hoff | Kamalika Banerjee | A. O. Hoff